louisiana glp-1 gi obstruction lawsuit in GLP-1 medications are now at the center of glp-1 bowel obstruction lawsuit in

Krivic, A., Anic, T., Seiwerth, S., Huljev, D., & Sikiric, P

GHK-Cu is a peptide that helps the body heal naturally

They can also help reduce appetite, supporting smaller meals and fewer cravings

Phase 1b/2a Subcutaneous Formulation (Obesity) Published: The Lancet, June 2025 Participants: 125 adults with overweight or obesity (BMI 27.039.9), aged 1855 Duration: Up to 36 weeks Dosing: Once-weekly subcutaneous amycretin, up to 60 mg Results: - Up to 22% absolute weight loss at 36 weeks (highest dose group) - Placebo-adjusted difference: approximately 24% - No weight-loss plateau observed at study end Safety: 81% of the 89 participants who reported a TEAE had gastrointestinal events